Ascidian Therapeutics
Edit info- Founded: 2020
- Location: Boston, MA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: ocular
- Drug types: OPH, NEU
- Lead product: ABCA4
- Funding: $50M A Oct 2022
- Investors: ATP
ascidian-tx.com linkedin.com job board
Business:
Mutated exon replacement
Drug notes:
7 add'l RD programs
About:
Ascidian Therapeutics is creating gene therapies that replace exons via selective splicing of pre-mRNA. The technology is called RNA exon editing. A designer RNA is used to replace mutated, disease-causing exons within pre-mRNA. Multiple continuous exons can be replaced. This gene therapy approach allows editing large portions of RNA (rather than just single base changes), avoids the risks of direct DNA editing, and does not alter endogenous gene expression levels. The company is named Ascidian, because their technology is based on a biological process that naturally occurs in ocean creatures called ascidians (also known as sea squirts). Ascidians use unique mechanisms of RNA splicing to re-engineer their transcriptome in developing from larvae to adults.
Jobs:
SVP of Regulatory and Quality
Boston|87 days ago
News:
Ascidian Therapeutics Launches to Rewrite RNA - PR Newswire
googlenews
Oct 12, 2022
Science/business updates
external-link
May 8, 2024 | Scientific Poster
Exon Editing of ABCA4 RNA in Human Retinal Explants and Non-Human Primate Retina for the
web
Dec 20, 2024
Science/business updates
external-link
FDA Clears First Clinical Trial of RNA Exon Editor Developed to Treat Stargardt Disease - CRISPR Medicine News
googlenews
Jan 31, 2024
Science/business updates
external-link
Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ...
crunchbase
Jan 29, 2024
Science/business updates
external-link
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
crunchbase
Jun 30, 2024
Funding-related
external-link
Always a pleasure to talk to our friends at Foundation Fighting Blindness!šļø
Check out thisĀ Eye on the CureĀ podcast episode with Robert Bell & host Ben Shaberman diving into the #STELLARClinicalTria
linkedin
Dec 18, 2024
Science/business updates
external-link
Roche and Ascidian enter neurological disease partnership worth over $1.8bn - PMLiVE
googlenews
Jun 19, 2024
Funding-related
external-link
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies - BioSpace
googlenews
Jun 18, 2024
Funding-related
external-link
Gene editing: DNA versus RNA - Drug Discovery News
googlenews
Feb 14, 2023
Science/business updates
external-link
Boston startup Ascidian Therapeutics charts vision for therapies that ārewrite RNAā - The Boston Globe
googlenews
Oct 12, 2022
Science/business updates
external-link
Ascidian Therapeutics rises from ATP's ocean floor with ...
fiercebiotech.com
Dec 18, 2024
Funding-related
external-link
Congratulations to Ascidian President and CEO, Michael Ehlers, MD, PhD, for being named to the #PharmaVoice100, recognizing individuals who are a driving force in the industry. Weāre proud to have Mik
linkedin
Oct 18, 2024
New hires
external-link
Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact
linkedin
Nov 18, 2024
New hires
external-link
Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting - PR Newswire
googlenews
May 9, 2023
Science/business updates
external-link
Roche partners with Ascidian Therapeutics to develop gene therapies
crunchbase
Jun 30, 2024
Science/business updates
external-link
Ascidian closes $50M financing to rewrite the rules of RNA splicing - BioWorld Online
googlenews
Oct 12, 2022
Funding-related
external-link
October 22, 2024 | BIOPHARMA DIVE
State of Play ā RNA editing: emerging from CRISPRās shadow
web
Dec 18, 2024
Science/business updates
external-link
RNA Rewriting to Treat Neurological Disease Focus of Ascidian, Roche Collaboration - Genetic Engineering & Biotechnology News
googlenews
Jun 18, 2024
Science/business updates
external-link
Roche Adds Another Neuro Alliance, Inking R&D Pact With RNA-Editing Startup Ascidian
crunchbase
Jun 24, 2024
Science/business updates
external-link
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
crunchbase
Jun 24, 2024
Science/business updates
external-link
For #WorldSightDay, we're celebrating Lucia and Sarafina, the āStargardt Sistersā ā who share an incredible bond in addition to a #StargardtDisease diagnosis. Weāre immensely grateful to their mom, Sa
linkedin
Oct 18, 2024
Science/business updates
external-link
Bradford Manning is the real master, and we are here for it!Ā Thank you, Brad, for inviting us to take part in your impressive master class on #StargardtDisease ā youāve created something really specia
linkedin
Oct 18, 2024
Science/business updates
external-link
Roche strikes neuro-focused partnership with RNA exon editing startup, worth as much as $1.8B - Endpoints News
googlenews
Jun 18, 2024
Funding-related
external-link
RNA-rewriting candidate moves into the clinic - Nature.com
googlenews
May 20, 2024
Science/business updates
external-link
Ascidian Therapeutics, Roche Enter Research Collaboration & License Agreement - Contract Pharma
googlenews
Jun 18, 2024
Science/business updates
external-link
June 24, 2024 | MedCity News
Roche Adds Another Neuro Alliance, Inking R&D Pact With RNA-Editing Startup Ascidia
web
Dec 18, 2024
Science/business updates
external-link
#TeamAscidian is closing out #BlindnessAwarenessMonth by gearing up for the last segment of the 'Journey Through Vision Loss' event at The Carroll Center for the Blind this Saturday, November 2.Ā Our o
linkedin
Dec 18, 2024
Science/business updates
external-link
Missed the āJourney Through Vision Lossā event at The Carroll Center for the Blind? You can still catch ourĀ #TeamAscidianĀ presentation,Ā 'Hope on the Horizon: ACDN-01 for Stargardt Disease.'Ā Special t
linkedin
Nov 18, 2024
Science/business updates
external-link
September 26, 2024 | ENDPOINTS
Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes
web
Dec 18, 2024
Science/business updates
external-link
#TeamAscidianĀ is thrilled to beĀ at the Alliance for Regenerative Medicineās 2024 Cell & Gene Meeting on the MesaĀ in Arizona. šµ Join us Wednesday morning as our Chief Financial and Business Officer,Ā D
linkedin
Oct 18, 2024
Science/business updates
external-link
ćććé£ē
ć«RNAē·Øéćéŗä¼åę²»ēććå®å
Øć«ćę°čę²»éØ - ę„ę¬ēµęøę°č
linkedin
Dec 18, 2024
Science/business updates
external-link
Roche wades deeper into RNA waters, paying Ascidian $42M to develop exon editing drugs
crunchbase
Jun 30, 2024
Funding-related
external-link
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases - PR Newswire
googlenews
Jun 18, 2024
Science/business updates
external-link
Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes to RNA - Endpoints News
googlenews
Sep 26, 2024
Science/business updates
external-link
September 10, 2024 | Publication
RNA Exon Editing: Splicing the way to treat human diseases
web
Dec 20, 2024
Science/business updates
external-link
Introducing Fierce Biotech's 2024 Fierce 15 - Fierce Biotech
googlenews
Aug 5, 2024
Science/business updates
external-link
Gwendolyn Wu and Ben Fidler of BioPharma Dive provide a state-of-play in the cutting-edge field of RNA editing.Ā As our own Michael Ehlers explains, āIt has all the features of a technology that could
linkedin
Nov 18, 2024
Science/business updates
external-link
RNA editing promises to go where DNA editing canāt Premium
crunchbase
Nov 7, 2024
Science/business updates
external-link
Roche partners with Ascidian Therapeutics to develop gene therapies - Reuters
googlenews
Jun 18, 2024
Science/business updates
external-link
The Petri Dish: MIT spinout gets $7M; Another biotech moves to Fort Point - The Business Journals
googlenews
Aug 15, 2024
Funding-related
external-link
Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting - PR Newswire
googlenews
Apr 25, 2024
Science/business updates
external-link
FDA Clears Ascidian for First-Ever RNA Editing Trial in US - BioSpace
googlenews
Jan 30, 2024
Science/business updates
external-link
Ascidianās RNA exon editor cleared to enter clinic for Stargardt disease - BioWorld Online
googlenews
Jan 30, 2024
Science/business updates
external-link
Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer - PR Newswire
googlenews
Mar 20, 2023
New hires
external-link
July 29, 2024 | Rare Insights Podcast
Rewriting RNA with Ascidian Therapeutics
web
Dec 18, 2024
Science/business updates
external-link
Ascidian Nets $50M to Rewrite RNA in Stargardt Disease and Beyond - BioSpace
googlenews
Oct 11, 2022
Funding-related
external-link
The Weekās 10 Biggest Funding Rounds: Enable And Autonomous Vehicle Startup May Mobility See Big Bucks
crunchbase
Nov 13, 2023
Funding-related
external-link
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing ...
crunchbase
Jun 22, 2024
Science/business updates
external-link
Ascidian Therapeutics Raises $50M in Series A Funding
crunchbase
Oct 13, 2022
Funding-related
external-link
Firm Advises Ascidian Therapeutics - Wilson Sonsini
googlenews
Nov 8, 2022
Funding-related
external-link
Roche wades deeper into RNA waters, paying Ascidian $42M to develop exon editing drugs - Fierce Biotech
googlenews
Jun 18, 2024
Funding-related
external-link
Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene Therapy - CGTLiveā¢
googlenews
May 2, 2023
Science/business updates
external-link
Chutes & LaddersāBIO CEO resigns amid reports of dissent within organization - Fierce Biotech
googlenews
Oct 14, 2022
New hires
external-link
Ascidian Therapeutics rises from ATP's ocean floor with $50M and Dyne's former CEO - Fierce Biotech
googlenews
Oct 12, 2022
Funding-related
external-link
Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1 ...
crunchbase
May 4, 2024
Science/business updates
external-link
Ascidian's RNA exon editor cleared to enter clinic for Stargardt disease
crunchbase
Jan 30, 2024
Science/business updates
external-link
5 RNA editing companies you should know about - Labiotech.eu
googlenews
Apr 19, 2024
Science/business updates
external-link
August 5, 2024 | Fierce Biotech
Introducing Fierce Biotechās 2024 Fierce 15
web
Dec 18, 2024
Science/business updates
external-link
Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact - Endpoints News
googlenews
Nov 14, 2024
New hires
external-link
5 RNA editing companies you should know about
crunchbase
May 4, 2024
Science/business updates
external-link
FDA Clears Ascidian for First-Ever RNA Editing Trial in US
crunchbase
Jan 30, 2024
Science/business updates
external-link
šAs 2024 comes to a close, weāre filled with gratitude for everyone on #TeamAscidian and the hard work and dedication that made this a milestone year. Wishing all of our team, and all of you, a restf
linkedin
Dec 20, 2024
New hires
external-link
Roche pays Ascidian $42M to develop RNA exon editing ...
fiercebiotech.com
Dec 18, 2024
Funding-related
external-link
December 6, 2024 | Foundation Fighting Blindness
Eye on the Cure Podcast, Episode 77: Dr. Bob Bell
web
Dec 18, 2024
Science/business updates
external-link
Deals Report: Roche licenses Ascidianās RNA editing tech for neuro - BioCentury
googlenews
Jun 25, 2024
Funding-related
external-link
Roche, local startup Ascidian sign $1.8B deal for neurological medicines
crunchbase
Jun 24, 2024
Funding-related
external-link
Roche Adds Another Neuro Alliance, Inking R&D Pact With RNA-Editing Startup Ascidian - MedCity News
googlenews
Jun 23, 2024
Science/business updates
external-link
First-ever RNA editing trial in US gets clearance, pitting āexon editingā technology against vision loss - Endpoints News
googlenews
Feb 2, 2024
Science/business updates
external-link
#ICYMI: Holiday drive-time is perfect for catching the latestĀ Foundation Fighting Blindness 'Eye on the Cure' podcastĀ featuring Robert Bell!šĀ Hear aboutĀ #RNAExonEditing, theĀ #STELLARClinicalTrial for
linkedin
Dec 24, 2024
Science/business updates
external-link
Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies - PR Newswire
googlenews
Jan 29, 2024
Science/business updates
external-link
Roche, local startup Ascidian sign $1.8B deal for neurological medicines - The Business Journals
googlenews
Jun 18, 2024
Funding-related
external-link
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
crunchbase
Jun 30, 2024
Science/business updates
external-link
Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal
crunchbase
Jun 30, 2024
Science/business updates
external-link
Ascidian Therapeutics raises $40m to advance drug development
crunchbase
Nov 9, 2023
Funding-related
external-link
Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO
crunchbase
Nov 8, 2023
Funding-related
external-link
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic - PR Newswire
googlenews
Apr 11, 2023
New hires
external-link
Ascidian Therapeutics launches with $50M to rewrite RNA - Labiotech.eu
googlenews
Oct 12, 2022
Funding-related
external-link
The Weekās 10 Biggest Funding Rounds: Odysseyās Epic Round, Uniswap Raises Big And Mini Golf Gets Cash
crunchbase
Oct 14, 2022
Funding-related
external-link
Sea creature-inspired biotech Ascidian surfaces with $50M and a new way to edit RNA - MedCity News
googlenews
Oct 12, 2022
Funding-related
external-link
Boston startup Ascidian Therapeutics charts vision for therapies that ārewrite RNAā
crunchbase
Oct 12, 2022
Science/business updates
external-link
The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma
linkedin
Dec 19, 2024
Science/business updates
external-link
Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO - PR Newswire
googlenews
Nov 8, 2023
Funding-related
external-link
ARVO LIVE: Ascidian Therapeutics' research into gene therapy - Ophthalmology Times
googlenews
Apr 25, 2023
Science/business updates
external-link
Ā© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com